Abstract
BackgroundFKB327 is a proposed biosimilar of the adalimumab reference product (ADL). This randomised, double-blind, Phase III study (NCT02260791; FKB327-002) evaluated the therapeutic equivalence of FKB327 and ADL in patients (pts)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have